N^1,N^1-Dimethylbiguanide hydrochloride （HDMBG,HCl） was introduced as an oral glucose-lowering agent to treat non-insulin dependent diabetes mellitus. In this paper, two solid complexes-trichlorotris（N^5-benzoyl-N^...N^1,N^1-Dimethylbiguanide hydrochloride （HDMBG,HCl） was introduced as an oral glucose-lowering agent to treat non-insulin dependent diabetes mellitus. In this paper, two solid complexes-trichlorotris（N^5-benzoyl-N^1,N^1-dimethylbiguanidato）neodymium, [Nd（BDMBG）3Cl3）, and chlorobis-[N^5-（o-carboxybenzoyl）-N^1,N^1- dimethylbiguanidato]neodymium, [Nd（CDMBG）2Cl], were synthesized and characterized by elemental analyses, fluorescence spectra, IR, UV, DG, DTA etc. Biological testings were conducted by diabetic rats and ESR. The results showed that both the antidiabetic activity and the inhibition rates （Ih） to superoxide anion free radical （O2） on lipid are in the order as follows： Nd（SDMBG）3 [tris（N^5-salicyloyl-N^1,N^1-dimethylbiguanidato）neodymium]〉 Nd（CDMBG）2Cl≈HDMBG·HCl 〉Nd（BDMBG）3Cl3. It was concluded that different substituents at the o-position of the benzoyl group may affect these two kinds of behaviour to a great extent.展开更多
目的:探讨六味地黄丸联合二甲双胍治疗2型糖尿病肾阴亏虚患者的临床疗效。方法:选取我院2015年1月-2018年1月诊断为2型糖尿病肾阴亏虚患者50例,随机数字法分为二甲双胍治疗组(对照组24例),六味地黄丸联合二甲双胍治疗组(观察组26例),疗...目的:探讨六味地黄丸联合二甲双胍治疗2型糖尿病肾阴亏虚患者的临床疗效。方法:选取我院2015年1月-2018年1月诊断为2型糖尿病肾阴亏虚患者50例,随机数字法分为二甲双胍治疗组(对照组24例),六味地黄丸联合二甲双胍治疗组(观察组26例),疗程4周;比较两组患者临床疗效、总症状积分、糖化血红蛋白(HbA1c)、餐后2 h血糖值(2 hours Postprandial Blood Glucose,2 h PBG)、空腹血糖(Glucose,GLU)、血脂水平,检测其空腹胰岛素水平(Fasting Insulin,FINS)、观察胰岛素抵抗(HOMA-IR)情况,及24 h尿微量白蛋白水平(24 h MAU)、不良反应情况。结果:观察组临床疗效明显优于对照组(P<0.05);治疗后观察组临床症状评分均低于对照组(P<0.05);治疗后,观察组HbA1c、2 h PBG、GLU水平均低于对照组(P<0.05);观察组血脂水平较对照组改善更明显(P<0.05);观察组患者FINS水平、HOMA-IR及24 h MAU较对照组下降更显著(P<0.05);两组间不良反应比较无差别(P>0.05)。结论:六味地黄丸加减联合二甲双胍治疗肾阴亏虚型2型糖尿病患者效果显著,减轻患者临床症状,能改善患者血糖、血脂水平及胰岛素抵抗,并减轻糖尿病肾功能损害。展开更多
基金Project supported by the National Natural Science Foundation of China （No. 20171019）.
文摘N^1,N^1-Dimethylbiguanide hydrochloride （HDMBG,HCl） was introduced as an oral glucose-lowering agent to treat non-insulin dependent diabetes mellitus. In this paper, two solid complexes-trichlorotris（N^5-benzoyl-N^1,N^1-dimethylbiguanidato）neodymium, [Nd（BDMBG）3Cl3）, and chlorobis-[N^5-（o-carboxybenzoyl）-N^1,N^1- dimethylbiguanidato]neodymium, [Nd（CDMBG）2Cl], were synthesized and characterized by elemental analyses, fluorescence spectra, IR, UV, DG, DTA etc. Biological testings were conducted by diabetic rats and ESR. The results showed that both the antidiabetic activity and the inhibition rates （Ih） to superoxide anion free radical （O2） on lipid are in the order as follows： Nd（SDMBG）3 [tris（N^5-salicyloyl-N^1,N^1-dimethylbiguanidato）neodymium]〉 Nd（CDMBG）2Cl≈HDMBG·HCl 〉Nd（BDMBG）3Cl3. It was concluded that different substituents at the o-position of the benzoyl group may affect these two kinds of behaviour to a great extent.
文摘目的:探讨六味地黄丸联合二甲双胍治疗2型糖尿病肾阴亏虚患者的临床疗效。方法:选取我院2015年1月-2018年1月诊断为2型糖尿病肾阴亏虚患者50例,随机数字法分为二甲双胍治疗组(对照组24例),六味地黄丸联合二甲双胍治疗组(观察组26例),疗程4周;比较两组患者临床疗效、总症状积分、糖化血红蛋白(HbA1c)、餐后2 h血糖值(2 hours Postprandial Blood Glucose,2 h PBG)、空腹血糖(Glucose,GLU)、血脂水平,检测其空腹胰岛素水平(Fasting Insulin,FINS)、观察胰岛素抵抗(HOMA-IR)情况,及24 h尿微量白蛋白水平(24 h MAU)、不良反应情况。结果:观察组临床疗效明显优于对照组(P<0.05);治疗后观察组临床症状评分均低于对照组(P<0.05);治疗后,观察组HbA1c、2 h PBG、GLU水平均低于对照组(P<0.05);观察组血脂水平较对照组改善更明显(P<0.05);观察组患者FINS水平、HOMA-IR及24 h MAU较对照组下降更显著(P<0.05);两组间不良反应比较无差别(P>0.05)。结论:六味地黄丸加减联合二甲双胍治疗肾阴亏虚型2型糖尿病患者效果显著,减轻患者临床症状,能改善患者血糖、血脂水平及胰岛素抵抗,并减轻糖尿病肾功能损害。
